Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936.
about
Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancerEscalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.Dose escalation with overdose control using a quasi-continuous toxicity score in cancer Phase I clinical trials.Toxicity-dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials.Adaptive dose-finding studies: a review of model-guided phase I clinical trials.The tumor targeted superantigen ABR-217620 selectively engages TRBV7-9 and exploits TCR-pMHC affinity mimicry in mediating T cell cytotoxicity.Control of established colon cancer xenografts using a novel humanized single chain antibody-streptococcal superantigen fusion protein targeting the 5T4 oncofetal antigen.Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α versus IFN-α.A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma.Escalation with Overdose Control is More Efficient and Safer than Accelerated Titration for Dose Finding.Interactive Software "Isotonic Design using Normalized Equivalent Toxicity Score (ID-NETS©TM)" for Cancer Phase I Clinical Trials.Staphylococcal entertotoxins of the enterotoxin gene cluster (egcSEs) induce nitrous oxide- and cytokine dependent tumor cell apoptosis in a broad panel of human tumor cells.Naptumomab estafenatox: a new immunoconjugate.Dose-toxicity models in oncology.Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin5T4 oncofoetal antigen: an attractive target for immune intervention in cancer.Gene therapy by membrane-expressed superantigen for alpha-fetoprotein-producing hepatocellular carcinoma.A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies.Recombinant Staphylococcal Enterotoxin Type A Stimulate Antitumoral Cytokines.Enhanced anti-tumor immunity by superantigen-pulsed dendritic cells.Incoherent dose-escalation in phase I trials using the escalation with overdose control approach.Escalation with Overdose Control Using Ordinal Toxicity Grades for Cancer Phase I Clinical TrialsNumber of Patients per Cohort and Sample Size Considerations Using Dose Escalation with Overdose Control
P2860
Q24645548-42255D29-94E7-460B-A2DB-A2F074DB45F8Q30757656-564E31B5-CE0D-444B-95F5-2F59D59D5459Q33714319-CC9D0E0B-A5D8-40F8-939C-B8E9DFD12B84Q33772533-7030B8AC-3617-4381-A7BE-8FF50D735021Q34001009-6DDB3AFF-2B6B-4478-AE3D-298B0440AC69Q35032671-9580161C-A024-421B-A33E-FB3A49A30891Q35149457-F3C68EC1-70E2-46BA-97D3-53839681EE2DQ35552042-73977E89-DBD7-4FCD-BD8B-173F835F74C4Q36609877-48441DF3-B603-41E5-936D-2FFD585A105FQ36879099-D46A6288-178E-4616-92FA-4CAA7A09E73CQ36924666-59419752-8863-4C69-AD9B-D6741213C0ADQ37090032-24A937EC-19D3-4310-9316-993F9CC71BBCQ37669341-607D72D5-8A2D-49DA-8CA6-F4A503F652FFQ37829437-19F4AADB-F922-4739-8039-65DC5DDA95C1Q38180315-7534A177-4EB5-4B88-8D89-2F9302940127Q38984929-A2C6C440-F80E-4651-BD5F-0E29D11B6DAAQ40253340-4D56472C-CCB9-4DF1-A3AB-A90C43551808Q41790792-70F78E0E-B1BD-47CF-9166-F5FD89156875Q42045636-E89BA7E6-AA40-410F-AF06-D78859C4A702Q53251883-323D021C-5D0A-4703-B765-32F24CBF0504Q54987395-84A82C1B-4040-4878-9F8F-F18B7DCFB14AQ58910958-823F784B-429F-48C8-BBDF-A442561DC2D6Q58910979-4661D3C9-6D04-4890-9705-07143AF60C7A
P2860
Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Individualized patient dosing ...... verdose control in PNU-214936.
@en
type
label
Individualized patient dosing ...... verdose control in PNU-214936.
@en
prefLabel
Individualized patient dosing ...... verdose control in PNU-214936.
@en
P2093
P356
P1476
Individualized patient dosing ...... verdose control in PNU-214936.
@en
P2093
André Rogatko
Corey Langer
Francisco Robert
Goran Forsberg
James S Babb
Joan Schiller
Jonathan D Cheng
Lars Rupert Engelhardt
Louis M Weiner
Olov Fernberg
P304
P356
10.1200/JCO.2004.12.034
P407
P577
2004-02-01T00:00:00Z